Pathways for bradykinin formation and inflammatory disease

Journal of Allergy and Clinical Immunology

Volumn 109, Issue 2, 2002, Pages 195-209

  Kaplan, Allen P ^a   Joseph, Kusumam ^a   Silverberg, Michael ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

Angioedema; Bradykinin; Factor XII; Kininase; Kininogen; Prekallikrein

Indexed keywords

ARGININE CARBOXYPEPTIDASE; BLOOD CLOTTING FACTOR 7; BRADYKININ; CYTOKERATIN; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEPARIN; HIGH MOLECULAR WEIGHT KININOGEN; ICATIBANT; PREKALLIKREIN; PYROPHOSPHATE; SILICATE; SULFATIDE; URATE; UROKINASE RECEPTOR;

ALLERGIC RHINITIS; AMINO ACID SEQUENCE; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ASTHMA; BINDING AFFINITY; BINDING SITE; CELL ACTIVATION; CELL MEMBRANE; DIABETES MELLITUS; HEART FAILURE; HEREDITY; HYPERTENSION; INFLAMMATORY DISEASE; MOLECULAR WEIGHT; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; REVIEW; SCLERODERMA; SIGNAL TRANSDUCTION;

EID: 0036174408     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1067/mai.2002.121316     Document Type: Article

References (158)

1. Tissue kallikreins. Structure, regulation, and participation in mammalian physiology and disease
2. Some data on two purified kininogens from human plasma
3. Limited proteolysis of human low molecular mass kininogen by tissue kallikrein. Isolation and characterization of the heavy and light chains
4. Bradykinin formation - Plasma and tissue pathways and cellular interactions
5. Autoactivation of human Hageman factor
6. Kinetics of activation and autoactivation of factor XII
7. Hageman factor substrates II. Human plasma prekallikrein. Mechanism of activation by Hageman factor and participation in Hageman factor-dependent fibrinolysis
8. Human blood coagulation factor XI: Purification, properties, and mechanism of activation by factor XII
9. Activation of human factor XI (partial thromboplastin antecedent) by factor XII (activated Hageman factor)
10. Identification of prekallikrein and high molecular weight kininogen as a complex in plasma
11. Association of factor XI and high molecular weight kininogen in human plasma
12. Structural organization of the human kininogen gene and a model for its evolution
13. Cloning and sequence analysis of cDNAs for high molecular weight and low molecular weight prekininogen
14. An enzyme in human plasma that inactivates bradykinin and kallidins
15. Studies of the digestion of bradykinin, lysyl bradykinin and kinin degradation products by carboxypeptidases A, B, and N
16. Second kininase in human blood plasma
17. Competitive antagonists of bradykinin
18. Pharmacology of bradykinin and related kinins
19. Kinin B1 receptors: A review
20. The involvement of bradykinin B1 and B2 receptor mechanisms in cytokine-induced mechanical hyperalgesia in the rat
21. 9 bradykinin by angiotensin converting enzyme
22. The mechanism of digestion of bradykinin and lysyl bradykinin (kallidin) in human serum: The role of carboxypeptidase, angiotensin converting enzyme, and determination of final degradation products
23. The coagulation-kinin pathway of human plasma
24. Activation of Hageman factor in solid and fluid phases. A critical role of kallikrein
25. Fletcher factor deficiency. A diminished rate of Hageman factor activation caused by absence of prekallikrein with abnormalities of coagulation, fibrinolysis, chemotactic activity, and kinin generation
26. The cleavage and formation of activated Hageman factor by autodigestion and by kallikrein
27. Amino acid sequence of human b factor XIIa
28. The relationship of structure and function in human Hageman factor. The association of enzymatic and binding activities with separate regions of the molecule
29. Amino acid sequence of the heavy chain of kinin α factor XIIa (activated Hageman factor)
30. A prealbumin activation of prekallikrein II. Derivation of activators of prekallikrein from active Hageman factor by digestion with plasmin
31. A prealbumin activation of prekallikrein
32. Formation and structure of human Hageman factor fragments
33. Mechanism of activation of the classical pathway of complement by Hageman factor fragment
34. Characterization of human blood coagulation factor XII cDNA
35. Characterization of a cDNA coding for human factor XII (Hageman factor)
36. Mapping of a putative surface-binding site of human coagulation factor XII
37. A monoclonal antibody recognizing an icosapeptide sequence in the heavy chain of human factor XII inhibits surface-catalyzed activation
38. Assessment of human coagulation factor XII (FXII) to chromosome 5 by cDNA hybridization to DNA from somatic cell hybrids
39. Identification of prekallikrein and high molecular weight kininogen as a complex in plasma
40. Protein-protein interactions in contact activation of blood coagulation. Binding of high molecular weight kininogen and the 5-(iodoacetamido) fiuorescein-labeled kininogen light chain to prekallikrein, kallikrein, and the separated kallikrein heavy and light chains
41. The mechanism by which the light chain of cleaved HMW kininogen augments the activation of prekallikrein, factor XI, and Hageman factor
42. Dissemination of contact activation in plasma by plasma kallikrein
43. A prealbumin activator of prekallikrein III. Appearance of chemotactic activity for human neutrophils by the conversion of human prekallikrein to kallikrein
44. 2 macroglobulin
45. Purified human plasma kallikrein aggregates human neutrophils
46. Human plasma kallikrein releases neutrophil elastase during blood coagulation
47. The activation of the alternative pathway C3 convertase by human plasma kallikrein
48. An intrinsic factor XII-prekallikrein-dependent pathway activates the human plasma renin-angiotensin system
49. Initiation of plasma prorenin activation by Hageman factor dependent conversion of plasma prekallikrein to kallikrein
50. Human plasma prekaltikrein is a zymogen to a serine protease that contains four tandem repeats
51. Factor XI activation in a revised model of blood coagulation
52. Activation of human blood coagulation factor XI, independent of factor XII. Factor XI is activated by thrombin and factor XIa in the presence of negatively charged surfaces
53. Mechanisms for the involvement of high molecular weight kininogen in surface-dependent reactions of Hageman factor
54. Role of high molecular weight kininogen in surface binding and activation of coagulation factor XI and prekallikrein
55. Amino acid sequence of human factor XI, a blood coagulation factor with four tandem repeats that are highly homologous with plasma prekallikrein
56. Human high molecular weight kininogen. Studies of structure-function relationships and proteolysis of the molecule occurring during contact activation of plasma
57. Characterization of human high molecular weight kininogen: Procoagulant activity associated with the light chain of kinin-free high molecular weight kininogen
58. Studies on human kininogen I. Isolation, characterization, and cleavage by plasma katlikrein of high molecular weight kininogen
59. Studies on human high molecular weight (HMW) kininogen II. Structural change in HMW kininogen by the action of human plasma kallikrein
60. Cleavage of high molecular weight kininogen by purified kallikreins and upon contact activation of plasma
61. Studies of the binding of prekaliikrein and factor XI to high molecular weight kininogen and its light chain
62. Primary structure requirements for the binding of human high molecular weight kininogen to prekallikrein and factor XI
63. Completion of the primary structure of human high molecular weight kininogen. The amino acid sequence of the entire heavy chain and evidence for its evolution by gene triplication
64. The amino acid sequence of the light chain of human high molecular mass kininogen
65. 2 cysteine protease inhibitors. Evidence from immunological, enzymological, and sequence data
66. Human high molecular weight kininogen as a thiol protease inhibitor: Presence of the entire inhibition capacity in the native form of heavy chain
67. Mapping of functional domains of human high molecular weight and low molecular weight kininogens using murine monoclonal antibodies
68. Identification of the binding site for plasma prekallikrein in human high molecular kininogen
69. In vitro activation of the contact (Hageman factor) system of plasma by heparin and chondroitin sulfate E
70. Mast cell derived heparin activates the contact system: A link to kinin generation in allergic reactions
71. Enzymatic activities of activated and zymogen forms of human Hageman factor (factor XII)
72. Role of surface in surface-dependent activation of Hageman factor (blood coagulation factor XII)
73. Prekallikrein deficiency in man
74. Activation and function of human Hageman factor. The role of high molecular weight kininogen and prekallikrein
75. The effects of high molecular weight kininogen on surfaceadsorbed fibrinogen
76. Human kininogen deficiency with diminished levels of plasminogen proactivator and prekallikrein associated with abnormalities of the Hageman factor-dependent pathways
77. Flaujeac trait: Deficiency of human plasma kininogen
78. Kininogen deficiency in Fitzgerald trait: Role of high molecular weight kininogen in clotting and fibrinolysis
79. The expression of high molecular weight kininogen on human umbilical vein endothelial cells
80. The binding of high molecular weight kininogen to cultured human endothelial cells
81. Human high molecular weight kininogen binds to human umbilical vein endothelial cells via its heavy and light chains
82. Identification of an endothelial cell binding site on kininogen domain D3
83. Mapping the cell binding site on high molecular weight kininogen domain 5
84. High molecular weight kininogen is exclusively membrane bound on endothelial cells to influence activation of vascular endothelium
85. Generation of the vasoactive peptide bradykinin from high molecular weight kininogen bound to human umbilical vein endothelial cells
86. Human Hageman factor (factor XII) and high molecular weight kininogen compete for the same binding site on human umbilical vein endothelial cells
87. Identification of zinc-dependent endothelial cell binding protein for high molecular weight kininogen and factor XII: Identity with the receptor that binds to the globular "heads" of C1q (gC1qR)
88. Isolation and characterization of the kininogen binding protein p33 from endothelial cells
89. The multiligand-binding protein of gC1qR, putative C1q receptor, is a mitochondrial protein
90. Intracellular localization of the human receptor for the globular domains of C1q
91. Cytokeratin 1 and gC1qR mediate high molecular weight kininogen binding to endothelial cells
92. Identification of cytokeratin 1 as a binding protein and presentation receptor for kininogens on endothelial cells
93. Mapping binding domains of kininogens on endothelial cells
94. Expression and colocalization of cytokeratin 1 and urokinase plasminogen activator receptor on endothelial cells
95. gC1qR/P32, a C1q-binding protein is a receptor for the 1n1B invasion protein of listeria monocytogenes
96. Interaction between complement receptor gC1qR and hepatitis C virus core protein inhibits T-lymphocyte proliferation
97. Binding of high molecular weight kininogen to human endothelial cells is mediated via a site within domains 2 and 3 of the urokinase receptor
98. Contact system: A vascular biology modulator with anticoagulant, profibrinolytic, anfiadhesive, and proinflammatory attributes
99. Interaction of single-chain urokinase-type plasminogen activator with human endothelial cells
100. Human umbilical vein endothelial cells possess binding sites for the globular head domain of C1q
101. Interaction of high molecular weight kininogen binding proteins with each other
102. Assembly and expression of an intrinsic factor IX activator complex on the surface of cultured human endothelial cells
103. High molecular weight kininogen utilizes heparan sulfate proteoglycans for accumulation on endothelial cells
104. Factor XIIdependent contact activation on endothelial cells and binding proteins gC1qR and cytokeratin 1
105. High molecular weight kininogen regulates prekallikrein assembly and activation on endothelial cells: A novel mechanism for contact activation
106. Factor XII does not initiate prekallikrein activation on endothelial cells
107. Contact activation: A revision
108. Activation of the kinin-forming cascade on the surface of endothelial cells
109. High molecular weight kininogen peptides inhibit the formation of kallikrein on endothelial cell surfaces and subsequent urokinase-dependent plasmin formation
110. Inhibition by C1 INH of Hageman factor fragment activation of coagulation, fibrinolysis, and kinin generation
111. The regulation of factor XII by plasma proteinase inhibitors
112. 2 macroglobulin-kallikrein complexes
113. Inactivation of factor XIa in human plasma assessed by measuring factor XIa-protease inhibitor complexes: Major role of C1inhibitor
114. A biochemical abnormality in hereditary angioneurotic edema
115. Synthesis of C1 inhibitor in fibroblasts from patients with type I and type II hereditary angioneurotic edema
116. Acquired C1 inhibitor deficiency in lymphosarcoma
117. Acquired C1 inhibitor deficiencies in lymphoproliferative diseases with serum immunoglobulin abnormalities
118. Acquired angioedema with lymphoprnliferative disorder. Association of C1 inhibitor deficiency with cellular abnormality
119. Lupus-erythematosus-like disease in three unrelated women with hereditary angioneurotic edema
120. Acquired C1-inhibitor deficiency associated with anti-idiotypic antibody to monoclonal immunoglobulin
121. Autoantibody-mediated acquired deficiency of C1 inhibitor
122. Demonstration of modified inactive first component of complement (C1) inhibitor in the plasmas of C1 inhibitor deficient patients
123. Acquired angioedema: Observations on the mechanisms of action of autoantibodies directed against C1 esterase inhibitor
124. Autoantibody facilitated cleavage of C1 inhibitor in autoimmune angioedema
125. Mechanism of action of anti-C1 inhibitor autoantibodies: Prevention of the formation of stable C1s-C1 INH complexes
126. The value of rocket immunoelectrophoresis for C4 activation in the evaluation of patients with angioedema or C1 inhibitor deficiency
127. Detection of hereditary angioneurotic edema by demonstration of a reduction in the second component of human complement
128. Kinin formation in hereditary angioedema plasma: Evidence against derivation from C2 and in support of "spontaneous" formation of bradykinin
129. Generation of bradykinin during incubation of hereditary angioedema plasma
130. Hereditary angioneurotic edema: Characterization of plasma kinin and vascular permeability-enhancing activates
131. Vascular reactions in hereditary angioedema
132. A radioimmunoassay for bradykinin in plasma and synovial fluid
133. Plasma bradykinin in angioedema
134. Prekaltikrein activation and high molecular weight kininogen consumption in hereditary angioedema
135. Detection of active kallikrein in induced blister fluids of hereditary angioedema plasma
136. Activation of factor XII and cleavage of high molecular weight kininogen during attacks in hereditary and acquired C1 inhibitor deficiencies
137. Unique C1 inhibitor dysfunction in a kindred without angioedema II. Identification of a Ala443ÆVal substitution and functional analysis of the recombinant mutant protein
138. 443) in determination of target protease specificity: Inhibition of complement and contact proteases
139. Local bradykinin generation in hereditary angioedema
140. Converting enzyme and bradykinin use in the lung
141. Mediator release after nasal airway challenge with allergen
142. Kinins are generated in vivo following nasal airway challenge of allergic individuals with allergen
143. Inflammatory mediators in late antigen-induced rhinitis
144. Influx of kininogens into nasal secretions after antigen challenge of allergic individuals
145. Plasma kallikrein during experimentally induced allergic rhinitis: Role in kinin formation and contribution to TAME esterase activity in nasal secretions
146. Concentrations of glandular kallikrein in human nasal secretions increase during experimentally induced allergic rhinitis
147. Detection of tissue kallikrein in the bronchoalveolar lavage fluid of asthmatic subjects
148. Bradykinin-induced bronchoconstriction in humans. Mode of action
149. Elevation of tissue kallikrein and kinin in the airways of asthmatic subjects following endobronchial allergen challenge
150. Immediate and late inflammatory responses to ragweed antigen challenge of the peripheral airways in allergic asthmatics. Cellular, mediator, and permeability changes
151. Role of kinins in seasonal allergic rhinitis: Icatibant, a bradykinin B2 receptor antagonist abolishes the hyperresponsiveness and nasal eosinophilia induced by allergen
152. Efficacy and tolerability of Icatibant (HOE 140) in patients with moderately severe chronic bronchial asthma
153. 2 receptors in allergen-induced bronchial hyperresponsiveness
154. Sensory neuropeptide release by bradykinin: Mechanisms and pathophysiological implications
155. Physiologic manifestations of human anaphylaxis
156. In vitro activation of the contact (Hageman factor) system of plasma by heparin and chondroitin sulfate E
157. Mast cell derived heparin activates the contact system if linked to kinin generation in allergic reactions
158. Heparin, derived in allergic reactions due to the activation of the contact system